Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis (SURPASS)
This study has been terminated.
(Majority of subjects who enrolled in the extension of the study had received on average 12 months of treatment.)
Sponsor:
Biogen Idec
Collaborator:
Elan Pharmaceuticals
Information provided by:
Biogen Idec
ClinicalTrials.gov Identifier:
NCT01058005
First received: January 26, 2010
Last updated: September 13, 2012
Last verified: September 2012
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been terminated. |
|---|---|
| Study Completion Date: | April 2012 |
| Primary Completion Date: | April 2012 (Final data collection date for primary outcome measure) |